Novartis has agreed to take actions aimed at meeting U.S. Administration priorities for drug pricing; additional Novartis ...

Novartis has announced an agreement with the US government to lower the prices of its medicines in the US and support ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate pelacarsen to a Phase III test of Eli Lilly’s next-gen Alzheimer's drug—are poised ...

Fintel reports that on January 6, 2026, Barclays upgraded their outlook for Novartis AG - Depositary Receipt (NYSE:NVS) from ...

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024. Novartis ...

Capital is flocking to a few high-growth AI plays and ignoring other opportunities because of the AI trend in the markets.

After Novartis drafted plans to wed its pharma and oncology businesses earlier this month, reports of potential layoffs poured in. Now, as Novartis taps prolific Wall Street analyst Ronny Gal, Ph.D., ...

Salesforce, Inc. (NYSE:CRM) is one of the Best Quality Stocks to Buy Before 2026. On December 17, Salesforce, Inc. (NYSE:CRM) ...

SAN FRANCISCO—Artificial intelligence is a big buzzword in R&D right now, but at Novartis, it's hard at work in the sales department, too. Amid far more meetings with digital companies at the J.P.

Novartis’ $3.2 billion bet on Chinook Therapeutics is taking off. Top-line phase 3 data show the acquired candidate improved a sign of kidney disease, positioning the Swiss drugmaker to apply for ...

Novartis announced the appointment of a new chief legal and compliance officer on Monday morning, following the departure of Klaus Moosmayer, who currently serves as chief ethics, risk and compliance ...

Novartis is carrying on with plans to lay off thousands of workers, CEO Vasant Narasimhan told Insider. Through layoffs and spinoffs, the Swiss giant expects to trim its headcount by about 30% by 2024 ...